Layer, Chiang, et al. Genome Biology
Beleaguered Arrowhead 'Cautiously Optimistic' About RNAi Deal, Closes Calando's Lab
Meanwhile, in a filing with the US Securities and Exchange Commission, Arrowhead warned that its fiscal 2009 operating losses and negative cash flows from operations "raises doubts about its ability to continue as a going concern over the next 12 months and beyond."
New to GenomeWeb? Register here quickly.